- Home
- Clinical Trials
Hives Study Dunedin 01
Hives Studiy
Dunedin
Are you suffering from recurrent hives that have no specific cause or trigger, do not respond to antihistamines and last for 6 weeks or longer?
You could have a condition called chronic spontaneous urticaria.
Momentum Clinical Research is testing an investigational treatment that aims to reduce symptoms and make life more comfortable for those who suffer from this condition.
Description
What to expect
Study details
Ages
18 years or older
Duration
The entire study will last about 17 months and includes 19 clinic visits. This includes a treatment period of approximately 13 months with 15 clinic visits. This will be followed by a 16 week follow up period with 4 clinic visits.
Compensation
Participants will be compensated for time and travel
Eligibility Criteria
You may be eligible to join this study if you:
- Are 18 years or older
- Have had recurrent hives (urticaria) that last for 6 weeks or longer.
- Are taking a regular dose of antihistamines.
Other inclusion and exclusion criteria will apply.
Locations
Description
Chronic spontaneous urticaria (CSU) is a condition that causes sufferers to break out in itchy hives that can last for 6 weeks or longer. Many people with this condition experience recurrent symptoms even when no external allergen or trigger is present, and many do not respond to antihistamine or other available treatments. Living with recurrent hives is uncomfortable and impacts the quality of life of those who have this condition and improved treatment options are needed.
CSU is caused by the inappropriate activation and degranulation of the skins mast cells. Momentum Clinical Research is conducting a study on an investigational treatment that is designed to reduce the activity and numbers of mast cells to treat people with CSU, reduce symptoms and improve quality of life.
What to expect
The investigational treatment will be given via injection and the study will evaluate the effectiveness of different dosages to reduce symptoms.
During the first 24 weeks of the study, participants will be randomly assigned to be given the active study treatment every 4 or 8 weeks, or a placebo every 4 weeks.
During the next 28 weeks, all participants will be assigned to receive the active study treatment every 4 or 8 weeks.
Regular assessments will be conducted every 4 weeks to monitor symptoms while on the investigational treatment.
Register your interest now to find out if you are eligible to participate and if this study is a good fit for you.
Apply now
Fill out your details, and our team will be in touch to discuss your potential involvement in this study and answer any questions you may have.
Momentum Clinical Research NZ is a member of the Global Site Holdings Group. Global Site Holdings Pty Limited ACN 668 977 062 trading as Momentum Clinical Research ABN 51 668 977 062 and our related entities (we, us, our), will use the Personal Information you have provided in the above form to review and respond to your enquiry, to contact you about any future trials or studies you may be eligible for, and otherwise in accordance with our Privacy Policy and as required and authorised by law. We may not be able to provide you with a complete response or a response at all to your enquiry if you do not provide the requested information. Our Privacy Policy also contains further information about how we collect, use, store or disclose your Personal Information, how you may seek access and correction of your Personal Information, and how you may make a complaint about a breach of privacy. If you have questions, please contact us at contact@momentumclinicalresearch.com.